AstraZeneca (AZN) Stock Slides Despite Positive Tezspire Trial Results

Key Takeaways

Table of Contents

AstraZeneca shares declined approximately 2% in pre-market hours despite encouraging clinical trial data
The company’s Tezspire drug successfully achieved both primary and secondary trial objectives for eosinophilic esophagitis
Trial results showed the treatment effectively reduced esophageal inflammation and enhanced patients’ ability to swallow versus placebo
As an approved asthma therapy, Tezspire delivered $1.13 billion in revenue during 2025
Analysts maintain a Strong Buy rating on AZN with a mean price target of $221.40, suggesting 33% potential upside

Shares of AstraZeneca declined nearly 2% during pre-market hours Thursday, despite the pharmaceutical giant announcing that Tezspire, its asthma medication, successfully achieved all primary objectives in a late-stage clinical trial for treating eosinophilic esophagitis.

AstraZeneca PLC, AZN

The medication was co-developed with Amgen, whose shares similarly declined following the announcement. Both companies’ stocks experienced downward pressure despite receiving what appeared to be favorable clinical data.

The trial demonstrated that Tezspire successfully achieved both its primary and secondary goals. Researchers observed that the medication significantly decreased inflammation in patients’ esophaguses while simultaneously improving their ability to swallow when compared to participants receiving a placebo.

Eosinophilic esophagitis represents a chronic inflammatory disorder affecting over 470,000 individuals across the United States. The condition creates significant eating challenges and anxiety, often causing food to move sluggishly through the esophagus or become lodged.

The therapeutic mechanism of Tezspire involves inhibiting TSLP, a protein that triggers inflammation associated with eosinophils, which are specialized white blood cells. This identical approach currently underlies the drug’s approved application for severe asthma treatment.

According to AstraZeneca, approximately half of all patients diagnosed with this condition, including younger patients, fail to achieve sufficient symptom management using existing first-line therapies. These conventional treatments encompass dietary modifications, swallowed corticosteroid medications, and proton pump inhibitor drugs.

Tezspire has received regulatory approval across the United States, European Union, and numerous additional markets as a supplementary therapy for severe asthma cases. The medication generated $1.13 billion in revenue for AstraZeneca throughout 2025.

Pipeline Challenges Continue for AstraZeneca

This encouraging Tezspire trial outcome follows multiple developmental setbacks for AstraZeneca throughout 2026. During July, Wainua, a medication co-developed alongside Ionis Pharmaceuticals, surprisingly missed its trial objectives for transthyretin amyloid cardiomyopathy, a severe cardiac condition.

Additionally, a late-stage clinical investigation of Ultomiris, targeting rare diseases, also produced disappointing results. In May, a United States regulatory committee declined approval for camizestrant, a breast cancer treatment, citing issues with the trial’s design methodology.

More recently this month, AstraZeneca discontinued a clinical study evaluating volrustomig for lung cancer after determining the treatment would likely fail to achieve its efficacy benchmarks.

Year-to-date performance shows AZN stock trading down 3.63% entering Thursday’s trading session.

Analyst Perspectives on AstraZeneca

Notwithstanding these developmental challenges, Wall Street analysts continue maintaining an optimistic stance on the company. TipRanks data shows AZN carries a Strong Buy consensus rating, supported by 12 Buy recommendations, 1 Hold rating, and 1 Sell rating.

The average analyst price target stands at $221.40, representing approximately 33% upside potential from present trading levels. The most optimistic forecast on Wall Street reaches $275.35.

The successful esophagitis trial outcome could potentially bolster Tezspire’s commercial prospects, particularly considering the medication already surpassed $1 billion in asthma-related revenue during 2025.

AstraZeneca has yet to disclose when it plans to submit regulatory applications based on these latest clinical findings.

✨ Limited Time Offer